cabergoline has been researched along with Recrudescence in 18 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (27.78) | 29.6817 |
| 2010's | 12 (66.67) | 24.3611 |
| 2020's | 1 (5.56) | 2.80 |
| Authors | Studies |
|---|---|
| Bandgar, T; Goel, A; Goroshi, M; Gupta, T; Jalali, R; Krishnatry, R; Lila, A; Memon, SS; Patil, V; Ramteke-Jadhav, S; Sankhe, S; Sarathi, V; Shah, A; Shah, NS; Thakkar, K | 1 |
| Deepak, DS; Lee, KO; Sek, KS | 1 |
| Arosio, M; Ferrante, E; Giavoli, C; Indirli, R; Mantovani, G; Sala, E | 1 |
| Jensen, TS; Jørgensen, JO; Kallestrup, MM; Kasch, H; Nielsen, E; Østerby, T | 1 |
| Hu, J; Yang, H; Zhang, W; Zheng, X | 1 |
| Anheim, M; Benabid, AL; Chabardès, S; Dowsey-Limousin, P; Krack, P; Pollak, P | 1 |
| Akutsu, H; Ishikawa, E; Matsumura, A; Suzuki, H; Takano, S; Watanabe, S; Yamamoto, T | 1 |
| Kharlip, J; Salvatori, R; Wand, GS; Yenokyan, G | 1 |
| Molitch, ME | 1 |
| Beauregard, H; Bruno, OD; Danilowicz, K; Godbout, A; Lacroix, A; Manavela, M | 1 |
| Arlt, S; Drillich, M; Fischer-Tenhagen, C; Heuwieser, W; Reinecke, A | 1 |
| Malkani, S; Mehta, NK; Ockene, I | 1 |
| Giampietro, A; Iacovazzo, D; Lugli, F | 1 |
| Auriemma, RS; Colao, A; Di Sarno, A; Gasperi, M; Grasso, LF; Guerra, E; Perone, Y; Pivonello, R | 1 |
| Cappabianca, P; Colao, A; Di Sarno, A; Di Somma, C; Lombardi, G; Pivonello, R | 1 |
| Couldwell, WT; Laws, ER; Weiss, MH | 1 |
| Kawai, M; Misumi, S; Morimatsu, M; Negoro, K; Ogasawara, J; Tada, Y | 1 |
| Biswas, M; Davies, JS; Evans, LM; Jadon, D; McEwan, P; Rees, DA; Scanlon, MF; Smith, J | 1 |
1 review(s) available for cabergoline and Recrudescence
| Article | Year |
|---|---|
Current drug withdrawal strategy in prolactinoma patients treated with cabergoline: a systematic review and meta-analysis.
Topics: Biomarkers, Tumor; Cabergoline; Dopamine Agonists; Drug Administration Schedule; Ergolines; Humans; Hyperprolactinemia; Pituitary Neoplasms; Prolactin; Prolactinoma; Recurrence; Time Factors; Treatment Outcome; Tumor Burden | 2015 |
17 other study(ies) available for cabergoline and Recrudescence
| Article | Year |
|---|---|
Cabergoline may act as a radioprotective agent in Cushing's disease.
Topics: Adolescent; Adult; Cabergoline; Child; Female; Follow-Up Studies; Humans; Male; Middle Aged; Outcome Assessment, Health Care; Pituitary ACTH Hypersecretion; Radiation-Protective Agents; Recurrence; Remission Induction; Retrospective Studies; Young Adult | 2020 |
Use of cabergoline for the management of persistent Cushing's disease in pregnancy.
Topics: Adult; Antineoplastic Agents; Cabergoline; Diagnosis, Differential; Ergolines; Female; Humans; Pituitary ACTH Hypersecretion; Pregnancy; Pregnancy Complications; Prenatal Diagnosis; Recurrence; Remission Induction | 2017 |
Cabergoline Withdrawal Before and After Menopause: Outcomes in Microprolactinomas.
Topics: Adenoma; Adolescent; Adult; Cabergoline; Dopamine Agonists; Female; Humans; Hyperprolactinemia; Middle Aged; Pituitary Neoplasms; Postmenopause; Premenopause; Prolactin; Prolactinoma; Recurrence; Remission Induction; Retrospective Studies; Risk; Treatment Outcome; Young Adult | 2019 |
Prolactinoma-associated headache and dopamine agonist treatment.
Topics: Adult; Aminoquinolines; Cabergoline; Case-Control Studies; Dopamine Agonists; Ergolines; Female; Headache; Humans; Hyperprolactinemia; Magnetic Resonance Imaging; Male; Middle Aged; Pituitary Neoplasms; Prolactinoma; Recurrence; Substance Withdrawal Syndrome | 2014 |
Subthalamic stimulation or subthalamic lesion for Parkinson's disease? A case report.
Topics: Adult; Antiparkinson Agents; Cabergoline; Chorea; Combined Modality Therapy; Deep Brain Stimulation; Equipment Failure; Ergolines; Female; Haloperidol; Humans; Magnetic Resonance Imaging; Parkinson Disease; Recurrence; Severity of Illness Index; Subthalamic Nucleus | 2015 |
Long-term results of cabergoline therapy for macroprolactinomas and analyses of factors associated with remission after withdrawal.
Topics: Adolescent; Adult; Cabergoline; Cavernous Sinus; Ergolines; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Invasiveness; Prolactin; Prolactinoma; Recurrence; Remission Induction; Retrospective Studies; Young Adult | 2017 |
Recurrence of hyperprolactinemia after withdrawal of long-term cabergoline therapy.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Cabergoline; Ergolines; Female; Humans; Hyperprolactinemia; Male; Middle Aged; Pituitary Neoplasms; Pregnancy; Pregnancy Complications, Neoplastic; Prognosis; Prolactinoma; Recurrence; Retrospective Studies; Time Factors; Withholding Treatment; Young Adult | 2009 |
Pituitary gland: can prolactinomas be cured medically?
Topics: Antineoplastic Agents, Hormonal; Cabergoline; Dopamine Agonists; Ergolines; Humans; Hyperprolactinemia; Meta-Analysis as Topic; Pituitary Gland; Pituitary Neoplasms; Prolactinoma; Recurrence; Withholding Treatment | 2010 |
Cabergoline monotherapy in the long-term treatment of Cushing's disease.
Topics: Adult; Aged; Cabergoline; Cohort Studies; Ergolines; Female; Follow-Up Studies; Humans; Hydrocortisone; Male; Middle Aged; Pituitary ACTH Hypersecretion; Recurrence; Retrospective Studies; Time Factors; Young Adult | 2010 |
[Inappropriate lactation syndrome in goats--case collection and experiences with mastectomy].
Topics: Animals; Cabergoline; Dopamine Agonists; Ergolines; Female; Galactorrhea; Goat Diseases; Goats; Mastectomy; Recurrence; Surgical Flaps; Treatment Outcome | 2011 |
Spontaneous coronary artery dissection during cabergoline therapy.
Topics: Adult; Angina Pectoris; Antineoplastic Agents, Hormonal; Aortic Dissection; Cabergoline; Cardiovascular Agents; Coronary Aneurysm; Coronary Angiography; Coronary Vasospasm; Ergolines; Female; Humans; Pituitary Neoplasms; Predictive Value of Tests; Prolactinoma; Recurrence; Risk Factors; Time Factors; Treatment Outcome | 2012 |
Ectopic posterior pituitary causing hyperprolactinemia.
Topics: Adult; Cabergoline; Choristoma; Diagnosis, Differential; Ergolines; Female; Hormone Antagonists; Humans; Hyperprolactinemia; Magnetic Resonance Imaging; Oligomenorrhea; Pituitary Diseases; Pituitary Gland, Posterior; Prolactin; Recurrence; Treatment Outcome | 2012 |
Results of a single-center observational 10-year survey study on recurrence of hyperprolactinemia after pregnancy and lactation.
Topics: Adult; Antineoplastic Agents; Breast Feeding; Cabergoline; Data Collection; Dopamine Agonists; Ergolines; Female; Humans; Hyperprolactinemia; Infertility, Female; Lactation; Observation; Pituitary Neoplasms; Pregnancy; Pregnancy Complications, Neoplastic; Pregnancy Outcome; Prolactinoma; Puerperal Disorders; Recurrence; Time Factors | 2013 |
Withdrawal of long-term cabergoline therapy for tumoral and nontumoral hyperprolactinemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Cabergoline; Dopamine Agonists; Ergolines; Female; Humans; Hyperprolactinemia; Magnetic Resonance Imaging; Male; Middle Aged; Pituitary Neoplasms; Prolactin; Prolactinoma; Prospective Studies; Recurrence; Withholding Treatment | 2003 |
Prolactinomas.
Topics: Antineoplastic Agents; Cabergoline; Ergolines; Follow-Up Studies; Humans; Hyperprolactinemia; Pituitary Neoplasms; Prolactin; Prolactinoma; Recurrence; Withholding Treatment | 2004 |
A case of postprandial cluster-like headache with prolactinoma: dramatic response to cabergoline.
Topics: Adolescent; Antineoplastic Agents; Cabergoline; Cluster Headache; Eating; Ergolines; Humans; Male; Pituitary Neoplasms; Prolactinoma; Recurrence; Treatment Outcome | 2005 |
Long-term remission following withdrawal of dopamine agonist therapy in subjects with microprolactinomas.
Topics: Adolescent; Adult; Antineoplastic Agents; Bromocriptine; Cabergoline; Dopamine Agonists; Ergolines; Female; Humans; Male; Middle Aged; Pituitary Neoplasms; Prolactinoma; Recurrence; Remission Induction; Retrospective Studies; Risk Factors; Time Factors; Treatment Outcome | 2005 |